Trial record 1 of 1 for:
NCT03938545
ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03938545 |
|
Recruitment Status :
Terminated
(Sponsor decision based on premature unblinding of treatment allocations necessitated by program-wide review)
First Posted : May 6, 2019
Results First Posted : September 22, 2022
Last Update Posted : September 22, 2022
|
Sponsor:
Immunovant Sciences GmbH
Information provided by (Responsible Party):
Immunovant Sciences GmbH
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of the current study is to assess the efficacy and safety/tolerability of three dose regimens of RVT-1401 in the treatment of active, moderate to severe GO participants. In addition, the study is designed to characterize the effect of RVT-1401 exposure on reduction in anti-TSHR IgG
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Graves' Ophthalmopathy (GO) | Drug: RVT-1401 (Administered via subcutaneous injection) Other: Placebo (Administered via subcutaneous injection) | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 65 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | ASCEND GO-2: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study of RVT-1401 for the Treatment of Patients With Active, Moderate to Severe Graves' Ophthalmopathy |
| Actual Study Start Date : | July 23, 2019 |
| Actual Primary Completion Date : | February 2, 2021 |
| Actual Study Completion Date : | April 15, 2021 |
Resource links provided by the National Library of Medicine
MedlinePlus related topics:
Eye Diseases
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Regimen A-RVT-1401
Regimen A= RVT-1401 680 mg weekly for 12 weeks
|
Drug: RVT-1401 (Administered via subcutaneous injection)
RVT-1401 is a fully human anti-neonatal Fc receptor (FcRn) monoclonal antibody. |
|
Experimental: Regimen B-RVT-1401
Regimen B= RVT-1401 340 mg weekly for 12 weeks
|
Drug: RVT-1401 (Administered via subcutaneous injection)
RVT-1401 is a fully human anti-neonatal Fc receptor (FcRn) monoclonal antibody. |
|
Experimental: Regimen C-RVT-1401
Regimen C= RVT-1401 255 mg weekly for 12 weeks
|
Drug: RVT-1401 (Administered via subcutaneous injection)
RVT-1401 is a fully human anti-neonatal Fc receptor (FcRn) monoclonal antibody. |
|
Placebo Comparator: Placebo
for 12 weeks
|
Other: Placebo (Administered via subcutaneous injection)
Placebo |
Primary Outcome Measures :
- Percentage of Participants With Proptosis Response at Week 13 [ Time Frame: Baseline; Week 13 ]Proptosis was assessed using an exophthalmometer. A proptosis response was defined as having at least a 2 millimeter (mm) reduction in study eye proptosis without a deterioration (at least a 2 mm increase) in the fellow eye at the same visit. The study eye was defined as the most severely affected eye at the baseline visit.
- Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (SAEs) [ Time Frame: From Baseline up to Week 20 ]AEs - any untoward medical occurrences in a participant, temporally associated with use of a medicinal product, whether or not considered related to the product. Clinically significant changes determined by the Investigator such as vital signs, ECGs, and clinical laboratory values were also reported as AEs. TEAE is defined as an AE that starts on or after the first dose of the study drug and before 30 days after the last dose of the study drug. SAEs were defined as any untoward medical occurrences that: resulted in death; were life-threatening; required hospitalization or prolongation of existing hospitalization; resulted in disability/incapacity; were congenital anomaly/birth defects; were important medical events that may have jeopardized the participant or may have required medical or surgical intervention; invasive or malignant cancers; and development of drug dependency or drug abuse.
Secondary Outcome Measures :
- Least Square Mean Percent Change From Baseline in Binding Anti-thyroid-stimulating Hormone Receptor (TSHR) Antibody Levels to Week 13 [ Time Frame: Baseline and Week 13 ]Binding Anti-TSHR antibody serum levels are directly associated with GO clinical features. Baseline was the last available assessment prior to the time of the first dose unless it was specified otherwise and was identified as Day 1. A negative change from baseline in binding anti-TSHR antibody levels indicated therapeutic benefit.
- Least Square Mean Percent Change From Baseline in Total IgG Levels [ Time Frame: Baseline and Week 13 ]Blood samples we collected to determine total IgG levels. Baseline was the last available assessment prior to the time of the first dose unless it was specified otherwise and was identified as Day 1. A negative change from baseline in the IgG levels indicated therapeutic benefit.
- Least Square Mean Percent Change From Baseline in IgG Subclasses 1, 2, 3 and 4 [ Time Frame: Baseline and Week 13 ]Blood samples were collected to determine IgG 1,2,3 and 4 levels. Baseline was the last available assessment prior to the time of the first dose unless it was specified otherwise and was identified as Day 1. A negative change from baseline in the IgG levels indicated therapeutic benefit.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Male or female ≥18 years of age.
- Clinical diagnosis of Graves' disease with hyperthyroidism associated with active, moderate to severe Graves' Ophthalmopathy (GO) with a Clinical Activity Score (CAS) ≥4 for the most severely affected eye at Screening and Baseline (on the 7-item scale).
- Onset of active GO within 9 months of screening.
- Moderate-to-severe active GO (not sight-threatening but has an appreciable impact on daily life), usually associated with one or more of the following: lid retraction ≥2 millimeters (mm), moderate or severe soft tissue involvement, proptosis ≥3 mm above normal for race and gender, and/or inconstant or constant diplopia.
- Other, more specific inclusion criteria are defined in the protocol
Exclusion Criteria:
- Use of any steroid (intravenous, oral, steroid eye drops) for the treatment of GO or other conditions within 3 weeks prior to Screening. Steroids cannot be initiated during the trial. Exceptions include topical and inhaled steroids which are allowed.
- Use of rituximab, tocilizumab, or any monoclonal antibody for immunomodulation within the past 9 months prior to Baseline.
- Total IgG level <6 grams per liter (g/L) at Screening.
- Absolute neutrophil count <1500 cells per meter squared (cells/mm^3) at Screening.
- Participants with decreased best corrected visual acuity due to optic neuropathy as defined by a decrease in vision of 2 lines on the Snellen chart, new visual field defect, or color defect secondary to optic nerve involvement within the last 6 months at Screening.
- Previous orbital irradiation or surgery for GO.
- Other, more specific exclusion criteria are defined in the protocol
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03938545
Locations
Show 25 study locations
Sponsors and Collaborators
Immunovant Sciences GmbH
Study Documents (Full-Text)
Documents provided by Immunovant Sciences GmbH:
Documents provided by Immunovant Sciences GmbH:
Study Protocol [PDF] August 9, 2019
Statistical Analysis Plan [PDF] May 20, 2022
| Responsible Party: | Immunovant Sciences GmbH |
| ClinicalTrials.gov Identifier: | NCT03938545 |
| Other Study ID Numbers: |
RVT-1401-2001 |
| First Posted: | May 6, 2019 Key Record Dates |
| Results First Posted: | September 22, 2022 |
| Last Update Posted: | September 22, 2022 |
| Last Verified: | August 2022 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Immunovant Sciences GmbH:
|
IMVT-1401 Graves' Orbitopathy Thyroid Eye Disease |
Additional relevant MeSH terms:
|
Eye Diseases Graves Ophthalmopathy Eye Diseases, Hereditary Graves Disease Exophthalmos Orbital Diseases Genetic Diseases, Inborn |
Goiter Thyroid Diseases Endocrine System Diseases Hyperthyroidism Autoimmune Diseases Immune System Diseases |